GlassScriptPhysician profile
Emil Hayek
NPI 1679675375
$378,985.95
in general payments reported to CMS, 2019-2025
34 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $51K · 2021: $52K · 2022: $33K · 2023: $46K · 2024: $25K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Food and Beverage: $6,374 · Travel and Lodging: $3,230 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,264.00 |
| Food and Beverage | $6,374.48 |
| Travel and Lodging | $3,230.00 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $113,504.32 | 2019-2025 | Jardiance |
| Amgen INC. | $95,018.46 | 2019-2025 | Repatha, Repatha |
| Lilly USA, LLC | $65,252.89 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $54,159.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $15,511.77 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $12,158.81 | 2023-2025 | |
| Pfizer INC. | $11,711.76 | 2019-2025 | |
| Esperion Therapeutics, INC. | $4,408.53 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $3,456.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $623.91 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $362.22 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Boston Scientific Corporation | $294.92 | 2019-2025 | General - Therapies, Watchman Flx |
| Abbott Laboratories | $243.65 | 2019-2024 | Diamondback Coronary |
| Novo Nordisk INC | $239.90 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $221.58 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $214.33 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $200.78 | 2019-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $199.66 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $194.42 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $178.28 | 2023-2025 | Edarbyclor, Edarbyclor, Edarbi |
| Alnylam Pharmaceuticals INC. | $140.56 | 2025 | Onpattro |
| Corcept Therapeutics | $119.44 | 2024-2025 | Korlym |
| Acutus Medical, INC. | $118.67 | 2019 | |
| Heartflow, INC. | $73.28 | 2024 | |
| Braemar Manufacturing, LLC | $68.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $57.41 | 2019-2022 | |
| Lundbeck LLC | $53.25 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $51.98 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $47.61 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $37.96 | 2019 | |
| Genzyme Corporation | $16.89 | 2022 | |
| Mannkind Corporation | $15.99 | 2025 | |
| Chiesi USA, INC. | $15.76 | 2025 | Juxtapid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Hayek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.